Hayarpi Javrushyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hayarpi Javrushyan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Nikolay Avtandilyan
Affiliation Research Institute of Biology, Yerevan State University, Yerevan, Armenia
9 shared publications - Armen Trchounian
Research Institute of Biology, Yerevan State University, Yerevan, Armenia
4 shared publications - Mikayel Ginovyan
Research Institute of Biology, Yerevan State University, Yerevan, Armenia
4 shared publications - Alina Maloyan
Oregon Health & Science University
2 shared publications - Anna Grigoryan
Faculty of Biology, Yerevan State University, Yerevan, Armenia
2 shared publications - Anna Karapetyan
Research Institute of Biology, Yerevan State University, Yerevan 0025, Armenia
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 60 (2 (269)) , 101-113
L-ARGININE METABOLISM IN CANCER: LINKING TUMOR INFLAMMATION, APOPTOSIS, AND ANGIOGENESIS
L-arginine metabolism has emerged as a central regulatory axis in cancer biology, integrating metabolic reprogramming, immune modulation, and tumor microenvironment remodeling. Cancer cells frequently rewire arginine uptake, synthesis, and degradation pathways to sustain proliferation, evade immune surveillance, and adapt to metabolic stress conditions. This metabolic flexibility is enabled through coordinated regulation of key enzymatic nodes, including argininosuccinate synthase 1, argininosuccinate lyase, arginase isoforms (ARG1 and ARG2), and nitric oxide synthases, which collectively control intracellular arginine availability and its downstream signaling outputs. In the tumor microenvironment, arginine metabolism becomes a competitive interface between malignant cells and immune populations. Tumors exploit arginine depletion through increased arginase activity in myeloid-derived suppressor cells and tumor-associated macrophages, leading to impaired T-cell activation and suppression of anti-tumor immunity. In parallel, nitric oxide generated from arginine metabolism exerts concentration-dependent effects that can either promote tumor progression through angiogenesis and survival signaling or induce cytotoxic stress and apoptosis at higher levels. Additionally, polyamine biosynthesis derived from arginine catabolism further supports tumor growth, chromatin remodeling, and resistance to cell death. This review provides a comprehensive synthesis of L-arginine metabolic pathways in cancer, with a particular focus on their roles in tumor-associated inflammation, apoptotic regulation, and angiogenesis. We also discuss therapeutic strategies targeting arginine dependency, including arginine deprivation therapies, arginase inhibition approaches, and emerging combination immunometabolic strategies, as well as key resistance mechanisms such as argininosuccinate synthase 1 re-expression and metabolic rewiring. Collectively, L-arginine metabolism represents a multifunctional metabolic hub that connects tumor progression with immune regulation and offers multiple promising therapeutic entry points in oncology.
- 29 September 2026
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 60 (2 (269)) , 101-113
Open AccessL-ARGININE METABOLISM IN CANCER: LINKING TUMOR INFLAMMATION, APOPTOSIS, AND ANGIOGENESIS
L-arginine metabolism has emerged as a central regulatory axis in cancer biology, integrating metabolic reprogramming, immune modulation, and tumor microenvironment remodeling. Cancer cells frequently rewire arginine uptake, synthesis, and degradation pathways to sustain proliferation, evade immune surveillance, and adapt to metabolic stress conditions. This metabolic flexibility is enabled through coordinated regulation of key enzymatic nodes, including argininosuccinate synthase 1, argininosuccinate lyase, arginase isoforms (ARG1 and ARG2), and nitric oxide synthases, which collectively control intracellular arginine availability and its downstream signaling outputs. In the tumor microenvironment, arginine metabolism becomes a competitive interface between malignant cells and immune populations. Tumors exploit arginine depletion through increased arginase activity in myeloid-derived suppressor cells and tumor-associated macrophages, leading to impaired T-cell activation and suppression of anti-tumor immunity. In parallel, nitric oxide generated from arginine metabolism exerts concentration-dependent effects that can either promote tumor progression through angiogenesis and survival signaling or induce cytotoxic stress and apoptosis at higher levels. Additionally, polyamine biosynthesis derived from arginine catabolism further supports tumor growth, chromatin remodeling, and resistance to cell death. This review provides a comprehensive synthesis of L-arginine metabolic pathways in cancer, with a particular focus on their roles in tumor-associated inflammation, apoptotic regulation, and angiogenesis. We also discuss therapeutic strategies targeting arginine dependency, including arginine deprivation therapies, arginase inhibition approaches, and emerging combination immunometabolic strategies, as well as key resistance mechanisms such as argininosuccinate synthase 1 re-expression and metabolic rewiring. Collectively, L-arginine metabolism represents a multifunctional metabolic hub that connects tumor progression with immune regulation and offers multiple promising therapeutic entry points in oncology.
- Open Access
- 11 September 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (9) , e70307
Cytotoxic Effects of Medicinal Plant Extracts on HeLa Cells via Redox Imbalance, L‐Arginine Metabolic Reprogramming, and Glycolytic Suppression
Cancer cells undergo metabolic reprogramming to sustain proliferation, resist apoptosis, and adapt to oxidative stress. In the present study, we comparatively evaluated the anticancer effects of four medicinal plant extracts ( Inula helenium, Hypericum alpestre, Rumex obtusifolius , and Alchemilla smirnovii ) on HeLa cervical cancer cells, with particular emphasis on oxidative stress, l ‐arginine metabolism, and cellular energy pathways. Cell viability was assessed using the MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) assay, while biochemical colorimetric methods were used to determine nitric oxide production, arginase and nitric oxide synthase activities, malondialdehyde levels, superoxide dismutase and catalase activities, proline content, and key glycolytic metabolites. Nuclear morphology changes consistent with apoptotic features were examined by Hoechst 33258 staining. All tested extracts exhibited cytotoxic effects in HeLa cells in a time‐ and concentration‐dependent manner, which were further enhanced when combined with the metabolic inhibitors l‐NAME (Nω‐nitro‐l‐arginine methyl ester) or nor‐NOHA (Nω‐hydroxy‐nor‐l‐arginine). Inula helenium showed the strongest potentiation in combination treatments. Several extracts significantly decreased arginase activity while increasing nitric oxide synthase activity and nitrite levels, indicating modulation of l‐arginine metabolism. Treatments also increased malondialdehyde levels and stimulated antioxidant enzyme activities, consistent with redox imbalance and oxidative stress–mediated cytotoxicity. In addition, Inula helenium and Alchemilla smirnovii reduced intracellular glucose, pyruvate, and lactate concentrations, suggesting partial modulation of glycolytic metabolism. Fluorescence microscopy revealed chromatin condensation, nuclear fragmentation, and apoptotic body formation, particularly after treatment with Hypericum alpestre and Rumex obtusifolius . These findings demonstrate that selected medicinal plant extracts exert cytotoxic effects by simultaneously modulating oxidative stress, amino acid metabolism, and energy pathways in cervical cancer cells. The investigated plants may represent promising sources of bioactive compounds for the development of complementary metabolic anticancer strategies.
- 11 September 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (9) , e70307
Open AccessCytotoxic Effects of Medicinal Plant Extracts on HeLa Cells via Redox Imbalance, L‐Arginine Metabolic Reprogramming, and Glycolytic Suppression
Cancer cells undergo metabolic reprogramming to sustain proliferation, resist apoptosis, and adapt to oxidative stress. In the present study, we comparatively evaluated the anticancer effects of four medicinal plant extracts ( Inula helenium, Hypericum alpestre, Rumex obtusifolius , and Alchemilla smirnovii ) on HeLa cervical cancer cells, with particular emphasis on oxidative stress, l ‐arginine metabolism, and cellular energy pathways. Cell viability was assessed using the MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) assay, while biochemical colorimetric methods were used to determine nitric oxide production, arginase and nitric oxide synthase activities, malondialdehyde levels, superoxide dismutase and catalase activities, proline content, and key glycolytic metabolites. Nuclear morphology changes consistent with apoptotic features were examined by Hoechst 33258 staining. All tested extracts exhibited cytotoxic effects in HeLa cells in a time‐ and concentration‐dependent manner, which were further enhanced when combined with the metabolic inhibitors l‐NAME (Nω‐nitro‐l‐arginine methyl ester) or nor‐NOHA (Nω‐hydroxy‐nor‐l‐arginine). Inula helenium showed the strongest potentiation in combination treatments. Several extracts significantly decreased arginase activity while increasing nitric oxide synthase activity and nitrite levels, indicating modulation of l‐arginine metabolism. Treatments also increased malondialdehyde levels and stimulated antioxidant enzyme activities, consistent with redox imbalance and oxidative stress–mediated cytotoxicity. In addition, Inula helenium and Alchemilla smirnovii reduced intracellular glucose, pyruvate, and lactate concentrations, suggesting partial modulation of glycolytic metabolism. Fluorescence microscopy revealed chromatin condensation, nuclear fragmentation, and apoptotic body formation, particularly after treatment with Hypericum alpestre and Rumex obtusifolius . These findings demonstrate that selected medicinal plant extracts exert cytotoxic effects by simultaneously modulating oxidative stress, amino acid metabolism, and energy pathways in cervical cancer cells. The investigated plants may represent promising sources of bioactive compounds for the development of complementary metabolic anticancer strategies.
- Open Access
- 9 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (6) , e71651
Evaluating the Efficacy of Polyphenol‐Enriched Plant Extracts and Pathway Modulators in the Bone Marrow to Suppress Breast Cancer Progression
Disseminated tumor cells (DTCs) in the bone marrow can survive in a dormant state and later reawaken to drive metastatic relapse. Hypoxia‐driven angiogenic signaling (HIF‐1α → VEGF), matrix remodeling (MMP‐2), and inflammation (COX‐2, TNF‐α) are central determinants of niche permissiveness for colonization. We investigated whether rational combinations of selected plant extracts with pathway‐targeting small molecules can reprogram the bone marrow microenvironment, suppress pro‐metastatic signaling, and limit tumor progression by promoting dormancy‐like states. Complementary in vitro and in vivo experiments were performed. Human breast cancer cell lines (MDA‐MB‐231, MCF‐7) were exposed to defined plant extracts and to modulators of nitric‐oxide/arginase signaling; endpoints included HIF‐1α, COX‐2, and MMP‐2 expression (Western blot, immunocytochemistry), and migration/invasion (real‐time assays). LC‐HRMS profiled extract composition. In vivo efficacy was tested in a DMBA‐induced rat breast cancer model with systemic administration of extracts alone and in combination with small‐molecule modulators; bone‐marrow biomarkers (VEGF‐α, TNF‐α, IL‐2, MMP‐2, COX‐2) were quantified by ELISA, bone‐marrow cells by histology, and tumor burden and survival were recorded. Plant extract treatments attenuated HIF‐1α, COX‐2, and MMP‐2 in cancer cells and markedly reduced TNF‐α‐driven migration and invasion in vitro. LC‐HRMS identified a reproducible polyphenol‐rich fingerprint across active fractions. In vivo, combined therapies produced consistent decreases in bone‐marrow VEGF‐α, MMP‐2, and COX‐2 and a concomitant increase in IL‐2; these biochemical changes correlated with substantially reduced tumor size, lower incidence of progressive disease, and improved survival compared with controls. Differential responses were observed depending on the small‐molecule companion (e.g., L‐NAME versus arginase inhibition), indicating pathway‐specific modulation of the niche. Histopathology confirmed reduced marrow atypia and diminished tumor infiltration in responding groups. Our integrated dataset supports a model in which coordinated suppression of hypoxia/angiogenesis, matrix remodeling, and inflammatory signaling in the bone‐marrow niche—achieved by combining plant extracts with targeted modulators—constrains metastatic progression, plausibly by enforcing or sustaining dormancy of disseminated tumor cells. These findings identify testable mechanistic nodes (HIF‐1α, VEGF, MMP‐2, COX‐2) for follow‐up causal studies and support further fractionation and translational evaluation of active phytochemicals as adjuncts to niche‐targeted anti‐metastatic strategies.
- 9 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (6) , e71651
Open AccessEvaluating the Efficacy of Polyphenol‐Enriched Plant Extracts and Pathway Modulators in the Bone Marrow to Suppress Breast Cancer Progression
Disseminated tumor cells (DTCs) in the bone marrow can survive in a dormant state and later reawaken to drive metastatic relapse. Hypoxia‐driven angiogenic signaling (HIF‐1α → VEGF), matrix remodeling (MMP‐2), and inflammation (COX‐2, TNF‐α) are central determinants of niche permissiveness for colonization. We investigated whether rational combinations of selected plant extracts with pathway‐targeting small molecules can reprogram the bone marrow microenvironment, suppress pro‐metastatic signaling, and limit tumor progression by promoting dormancy‐like states. Complementary in vitro and in vivo experiments were performed. Human breast cancer cell lines (MDA‐MB‐231, MCF‐7) were exposed to defined plant extracts and to modulators of nitric‐oxide/arginase signaling; endpoints included HIF‐1α, COX‐2, and MMP‐2 expression (Western blot, immunocytochemistry), and migration/invasion (real‐time assays). LC‐HRMS profiled extract composition. In vivo efficacy was tested in a DMBA‐induced rat breast cancer model with systemic administration of extracts alone and in combination with small‐molecule modulators; bone‐marrow biomarkers (VEGF‐α, TNF‐α, IL‐2, MMP‐2, COX‐2) were quantified by ELISA, bone‐marrow cells by histology, and tumor burden and survival were recorded. Plant extract treatments attenuated HIF‐1α, COX‐2, and MMP‐2 in cancer cells and markedly reduced TNF‐α‐driven migration and invasion in vitro. LC‐HRMS identified a reproducible polyphenol‐rich fingerprint across active fractions. In vivo, combined therapies produced consistent decreases in bone‐marrow VEGF‐α, MMP‐2, and COX‐2 and a concomitant increase in IL‐2; these biochemical changes correlated with substantially reduced tumor size, lower incidence of progressive disease, and improved survival compared with controls. Differential responses were observed depending on the small‐molecule companion (e.g., L‐NAME versus arginase inhibition), indicating pathway‐specific modulation of the niche. Histopathology confirmed reduced marrow atypia and diminished tumor infiltration in responding groups. Our integrated dataset supports a model in which coordinated suppression of hypoxia/angiogenesis, matrix remodeling, and inflammatory signaling in the bone‐marrow niche—achieved by combining plant extracts with targeted modulators—constrains metastatic progression, plausibly by enforcing or sustaining dormancy of disseminated tumor cells. These findings identify testable mechanistic nodes (HIF‐1α, VEGF, MMP‐2, COX‐2) for follow‐up causal studies and support further fractionation and translational evaluation of active phytochemicals as adjuncts to niche‐targeted anti‐metastatic strategies.
- Open Access
- 15 December 2025
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 59 (3 (267)) , 113-121
ALTERATIONS IN ARGINASE ACTIVITY, NITRIC OXIDE, AND MDA LEVELS IN BONE MARROW DURING DMBA-INDUCED BREAST CANCER IN RATS
This study investigates the therapeutic potential of herbal extracts to mitigate bone marrow damage during DMBA-induced breast cancer and its treatment in rats. Untreated tumor-bearing rats showed elevated arginase activity and malondialdehyde (MDA) levels with reduced nitric oxide (NO) bioavailability. Treatment with herbal extract combined with the arginase inhibitor nor-NOHA, significantly reduced MDA and restored NO levels, demonstrating antioxidant and protective effects on the bone marrow. Conversely, combining a NOS inhibitor (L-NAME) with herbal extract exacerbated oxidative damage. The findings support using specific phytotherapeutics as adjuvants to conventional cancer therapy to maintain bone marrow integrity.
- 15 December 2025
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 59 (3 (267)) , 113-121
Open AccessALTERATIONS IN ARGINASE ACTIVITY, NITRIC OXIDE, AND MDA LEVELS IN BONE MARROW DURING DMBA-INDUCED BREAST CANCER IN RATS
This study investigates the therapeutic potential of herbal extracts to mitigate bone marrow damage during DMBA-induced breast cancer and its treatment in rats. Untreated tumor-bearing rats showed elevated arginase activity and malondialdehyde (MDA) levels with reduced nitric oxide (NO) bioavailability. Treatment with herbal extract combined with the arginase inhibitor nor-NOHA, significantly reduced MDA and restored NO levels, demonstrating antioxidant and protective effects on the bone marrow. Conversely, combining a NOS inhibitor (L-NAME) with herbal extract exacerbated oxidative damage. The findings support using specific phytotherapeutics as adjuvants to conventional cancer therapy to maintain bone marrow integrity.
- Open Access
Elucidating the Impact of Hypericum alpestre Extract and L-NAME on the PI3K/Akt Signaling Pathway in A549 Lung Adenocarcinoma Cells
Plants within the Hypericaceae family have been traditionally used for their medicinal properties, showcasing a wide range of effects such as antibacterial, antiviral, and antioxidant qualities. Hypericum alpestre (HA) extracts have exhibited significant cytotoxicity against various cancer cell lines. The phenolic compounds found in HA extracts have attracted attention for their potential in cancer prevention. L-NAME, known for its ability to inhibit nitric oxide synthase (NOS) activity, has emerged as a promising approach in cancer therapy. However, the precise molecular mechanisms underlying the anticancer effects of HA and L-NAME remain unclear. This study aims to clarify the impact of HA and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma cells, with a specific focus on TNFa/COX-2 and VEGFa/MMP-2 pathways. In silico analysis, they identified the compounds with the highest affinity for PI3K/Akt, a finding validated by subsequent in vitro experiments. Furthermore, the combination of herbs and L-NAME exhibited superior efficacy compared to the herb and 5-FU combination, as evidenced by the promotion of apoptosis. Both the herb alone and the combination of the herb with L-NAME demonstrated inhibitory effects on the TNFa/COX-2 and VEGFa/MMP-2 pathways. This therapeutic approach is hypothesized to operate through the PI3k/Akt cell signaling pathway. A better understanding of the interaction between HA polyphenols and PI3K/Akt signaling could pave the way for novel therapeutic strategies against cancer, including drug-resistant tumors.
Open AccessElucidating the Impact of Hypericum alpestre Extract and L-NAME on the PI3K/Akt Signaling Pathway in A549 Lung Adenocarcinoma Cells
Plants within the Hypericaceae family have been traditionally used for their medicinal properties, showcasing a wide range of effects such as antibacterial, antiviral, and antioxidant qualities. Hypericum alpestre (HA) extracts have exhibited significant cytotoxicity against various cancer cell lines. The phenolic compounds found in HA extracts have attracted attention for their potential in cancer prevention. L-NAME, known for its ability to inhibit nitric oxide synthase (NOS) activity, has emerged as a promising approach in cancer therapy. However, the precise molecular mechanisms underlying the anticancer effects of HA and L-NAME remain unclear. This study aims to clarify the impact of HA and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma cells, with a specific focus on TNFa/COX-2 and VEGFa/MMP-2 pathways. In silico analysis, they identified the compounds with the highest affinity for PI3K/Akt, a finding validated by subsequent in vitro experiments. Furthermore, the combination of herbs and L-NAME exhibited superior efficacy compared to the herb and 5-FU combination, as evidenced by the promotion of apoptosis. Both the herb alone and the combination of the herb with L-NAME demonstrated inhibitory effects on the TNFa/COX-2 and VEGFa/MMP-2 pathways. This therapeutic approach is hypothesized to operate through the PI3k/Akt cell signaling pathway. A better understanding of the interaction between HA polyphenols and PI3K/Akt signaling could pave the way for novel therapeutic strategies against cancer, including drug-resistant tumors.
- Open Access
- 18 December 2023
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 57 (3 (262)) , 238-247
THE CYTOTOXIC PROPERTIES OF $ALCHEMILLA~SMIRNOVII$ EXTRACT ON THE HELA CANCER CELLS VIA DOWNREGULATION OF ARGINASE ACTIVITYPlants of the genus Alchemilla are well known for their pharmacological effects. Alchemilla smirnovii Juz., also known as lady's mantle possessed high growth-inhibiting properties against cancer cells according to earlier reports. We aimed to explore the anticancer modulatory effect of A. smirnovii extract toward 5-fluorouracil and elucidate the possible mechanism of its cytotoxic action in the HeLa cancer cell model. Synergistic interactions of plant extract with the chemotherapeutic agent were assessed by MTT assay. Based on obtained data the ethanol extract of A. smirnovii exhibits synergistic effects, enhancing the growth-inhibiting properties of 5-fluorouracil when used together. Additionally, the extract leads to a reduction in arginase activity and an elevation in the level of MDA․ This implies that A. smirnovii induces oxidative stress, and can potentially cause apoptosis in cancer cells.
- 18 December 2023
- Published by Yerevan State University in Proceedings of the YSU B: Chemical and Biological Sciences
- Vol. 57 (3 (262)) , 238-247
Open AccessTHE CYTOTOXIC PROPERTIES OF $ALCHEMILLA~SMIRNOVII$ EXTRACT ON THE HELA CANCER CELLS VIA DOWNREGULATION OF ARGINASE ACTIVITYPlants of the genus Alchemilla are well known for their pharmacological effects. Alchemilla smirnovii Juz., also known as lady's mantle possessed high growth-inhibiting properties against cancer cells according to earlier reports. We aimed to explore the anticancer modulatory effect of A. smirnovii extract toward 5-fluorouracil and elucidate the possible mechanism of its cytotoxic action in the HeLa cancer cell model. Synergistic interactions of plant extract with the chemotherapeutic agent were assessed by MTT assay. Based on obtained data the ethanol extract of A. smirnovii exhibits synergistic effects, enhancing the growth-inhibiting properties of 5-fluorouracil when used together. Additionally, the extract leads to a reduction in arginase activity and an elevation in the level of MDA․ This implies that A. smirnovii induces oxidative stress, and can potentially cause apoptosis in cancer cells.
- 13 August 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 261-275
Anti-cancer effect of in vivo inhibition of nitric oxide synthase in a rat model of breast cancer
- 13 August 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 261-275
Anti-cancer effect of in vivo inhibition of nitric oxide synthase in a rat model of breast cancer
- 7 April 2022
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 126, 104763
Antihyperglycemic activity of L-norvaline and L-arginine in high-fat diet and streptozotocin-treated male rats
- 7 April 2022
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 126, 104763
Antihyperglycemic activity of L-norvaline and L-arginine in high-fat diet and streptozotocin-treated male rats
- 1 March 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 285, 103598
The effects of NO on the urea cycle pathway in short-term intermittent hypobaric hypoxia in rats
- 1 March 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 285, 103598
The effects of NO on the urea cycle pathway in short-term intermittent hypobaric hypoxia in rats
- 17 October 2019
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 111, 104316
The potential therapeutic effect of NG-hydroxy-nor-L-arginine in 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats
- 17 October 2019
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 111, 104316
The potential therapeutic effect of NG-hydroxy-nor-L-arginine in 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats